Benchmarking Patient Engagement Capabilities and Preparedness of Drug Development Sponsors.

Autor: Kim JY; Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA, 02111, USA. Jennifer_y.kim@tufts.edu., Acelas MPB; Drug Information Association, Washington, DC, USA., Granville CA; Drug Information Association, Washington, DC, USA., Getz K; Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA, 02111, USA.
Jazyk: angličtina
Zdroj: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2023 Sep; Vol. 57 (5), pp. 1040-1049. Date of Electronic Publication: 2023 Jun 19.
DOI: 10.1007/s43441-023-00545-x
Abstrakt: Consistent implementation and measurement of patient engagement initiatives across the industry have remained aspirational and elusive despite strong interest in adopting patient-centric approaches. One factor contributing to this inertia stems from a lack of standardized implementation of patient engagement activities, which varies widely from company to company, making it difficult to track and measure. Further, empirical evidence mapping the impact of patient engagement capabilities on clinical research outcomes has remained sparse. To address this gap, the Drug Information Association (DIA) and Tufts Center for the Study of Drug Development (Tufts CSDD) at the Tufts University School of Medicine developed and administered an assessment tool that companies can use to not only evaluate their organization's patient engagement capabilities and implementation preparedness but can also measure the impact of such activities on trial outcomes. Results showed that while most organizations are providing logistical support to increase patient engagement in the form of travel stipends, accommodation, and financial incentives, most are not implementing more involved forms of patient engagement such as gathering patient input through patient input panels or patient steering committees. This paper discusses the process for designing and administering this assessment tool, the results of the assessment, and future implications.
(© 2023. The Author(s), under exclusive licence to The Drug Information Association, Inc.)
Databáze: MEDLINE
Externí odkaz: